InsidersTradesSigma
申报总数
公司
▲ 买入（46 笔）
▼ 卖出（85 笔）
内部人交易记录
董事已披露买入
46
已披露卖出
85
T+90 胜率
47%
T+90 平均收益
-8.2%
基于 15 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the detailed record of transactions filed by Orbimed Advisors Llc, Board Member. Officer active across 46 companies, notably SpringWorks Therapeutics, Inc.. In total, 165 disclosures have been logged. Split: 46 buys · 85 sells. Total volume traded: €372.4m. Activity tracked since 7 June 2021. The latest transaction was filed on 10 August 2026 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Orbimed Advisors Llc
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报165 总计
1,039,996 股Common StockSEC:0000947871-26-000784:0
1,049,283 股Common StockSEC:0000947871-26-000784:1
625,000 股@ US$16.00Common StockSEC:0000947871-26-000784:2
标准退出：2026年11月8日 (T+90)
9,132,420 股Common StockSEC:0000947871-26-000782:0
1,666,667 股@ US$18.001.38% mcap85.9% 占其流量Common StockSEC:0000947871-26-000782:1
标准退出：2026年11月5日 (T+90)
273,333 股@ US$18.000.23% mcap14.1% 占其流量Common StockSEC:0000947871-26-000782:2
标准退出：2026年11月5日 (T+90)
1,000,000 股@ US$15.00100.0% 占其流量Common StockSEC:0000947871-26-000733:1
标准退出：2026年10月25日 (T+90)
348,825 股Common StockSEC:0000947871-26-000733:0
85,918 股@ US$44.860.19% mcap13.5% 占其流量Common StockSEC:0000947871-26-000694:0
24,846 股Common StockSEC:0000947871-26-000653:0
1,477 股Common StockSEC:0000947871-26-000653:1
46,776 股Common StockSEC:0000947871-26-000653:3
787,024 股Common StockSEC:0000947871-26-000653:2
597,729 股@ US$1.674.37% mcap100.0% 占其流量Common StockSEC:0000947871-26-000481:0
标准退出：2026年7月15日 (T+90)
1,689,189 股@ US$4.441.84% mcap41.8% 占其流量Common StockSEC:0000947871-26-000461:0
标准退出：2026年7月20日 (T+90)
1,126,126 股@ US$4.441.23% mcap27.9% 占其流量Common StockSEC:0000947871-26-000461:1
标准退出：2026年7月20日 (T+90)
52,397 股@ US$44.680.11% mcap9.2% 占其流量Common StockSEC:0000947871-26-000458:0
2,948 股@ US$44.520.0063% mcap0.5% 占其流量Common StockSEC:0000947871-26-000458:1
47,814 股@ US$44.510.10% mcap8.4% 占其流量Common StockSEC:0000947871-26-000446:0
235,863 股@ US$44.640.50% mcap41.4% 占其流量Common StockSEC:0000947871-26-000446:1
226,906 股@ US$45.340.49% mcap40.5% 占其流量Common StockSEC:0000947871-26-000446:2
29,319 股@ US$6.531.6% 占其流量Common StockSEC:0000947871-26-000421:0
2,400 股@ US$6.380.1% 占其流量Common StockSEC:0000947871-26-000421:1
32,523 股@ US$6.291.7% 占其流量Common StockSEC:0000947871-26-000421:2
40,416 股@ US$6.522.2% 占其流量Common StockSEC:0000947871-26-000421:3
165 条申报中的 25 条
About Orbimed Advisors Llc
ORBIMED ADVISORS LLC is a Board Member and has filed 157 disclosures in total. Across the 157 sampled recent filings, the reported amounts are EUR 95922088 in buys and EUR 305819195 in sells, with Cession shown as the modal transaction nature. Recent filings include activity in Sierra Oncology, Inc., Verona Pharma plc, Xtant Medical Holdings, Inc., Disc Medicine, Inc., Sionna Therapeutics, Inc. and Keros Therapeutics, Inc., over the period from 2021-06-09 to 2026-07-09.
